Avandia increases some cardiovascular risks but not others
This article was originally published in Scrip
A large-scale postmarketing study of GlaxoSmithKline's thiazolidinedione Avandia (rosiglitazone) has challenged some beliefs that it increases the risk of cardiac death, but confirms that the drug more than doubles the risk of heart failure.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.